<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yuan B</submitter><funding>Natural Science Foundation of Zhejiang Province</funding><funding>China Postdoctoral Science Foundation</funding><funding>National Natural Science Foundation of China</funding><pagination>e111549</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9929636</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>42(4)</volume><pubmed_abstract>YAP/TAZ transcriptional co-activators play pivotal roles in tumorigenesis. In the Hippo pathway, diverse signals activate the MST-LATS kinase cascade that leads to YAP/TAZ phosphorylation, and subsequent ubiquitination and proteasomal degradation by SCF&lt;sup>β-TrCP&lt;/sup> . When the MST-LATS kinase cascade is inactive, unphosphorylated or dephosphorylated YAP/TAZ translocate into the nucleus to mediate TEAD-dependent gene transcription. Hippo signaling-independent YAP/TAZ activation in human malignancies has also been observed, yet the mechanism remains largely elusive. Here, we report that the ubiquitin E3 ligase HERC3 can promote YAP/TAZ activation independently of its enzymatic activity. HERC3 directly binds to β-TrCP, blocks its interaction with YAP/TAZ, and thus prevents YAP/TAZ ubiquitination and degradation. Expression levels of HERC3 correlate with YAP/TAZ protein levels and expression of YAP/TAZ target genes in breast tumor cells and tissues. Accordingly, knockdown of HERC3 expression ameliorates tumorigenesis of breast cancer cells. Our results establish HERC3 as a critical regulator of the YAP/TAZ stability and a potential therapeutic target for breast cancer.</pubmed_abstract><journal>The EMBO journal</journal><pubmed_title>HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.</pubmed_title><pmcid>PMC9929636</pmcid><funding_grant_id>2020M671701</funding_grant_id><funding_grant_id>31730057</funding_grant_id><funding_grant_id>LD21C070001</funding_grant_id><funding_grant_id>91940302</funding_grant_id><funding_grant_id>32200568</funding_grant_id><pubmed_authors>Shen L</pubmed_authors><pubmed_authors>Liang T</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Xu P</pubmed_authors><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Zhao B</pubmed_authors><pubmed_authors>Cao J</pubmed_authors><pubmed_authors>Luo H</pubmed_authors><pubmed_authors>Qiu Y</pubmed_authors><pubmed_authors>Feng XH</pubmed_authors><pubmed_authors>Cao X</pubmed_authors><pubmed_authors>Yuan B</pubmed_authors><pubmed_authors>Shi A</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Shi J</pubmed_authors><pubmed_authors>Yu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.</name><description>YAP/TAZ transcriptional co-activators play pivotal roles in tumorigenesis. In the Hippo pathway, diverse signals activate the MST-LATS kinase cascade that leads to YAP/TAZ phosphorylation, and subsequent ubiquitination and proteasomal degradation by SCF&lt;sup>β-TrCP&lt;/sup> . When the MST-LATS kinase cascade is inactive, unphosphorylated or dephosphorylated YAP/TAZ translocate into the nucleus to mediate TEAD-dependent gene transcription. Hippo signaling-independent YAP/TAZ activation in human malignancies has also been observed, yet the mechanism remains largely elusive. Here, we report that the ubiquitin E3 ligase HERC3 can promote YAP/TAZ activation independently of its enzymatic activity. HERC3 directly binds to β-TrCP, blocks its interaction with YAP/TAZ, and thus prevents YAP/TAZ ubiquitination and degradation. Expression levels of HERC3 correlate with YAP/TAZ protein levels and expression of YAP/TAZ target genes in breast tumor cells and tissues. Accordingly, knockdown of HERC3 expression ameliorates tumorigenesis of breast cancer cells. Our results establish HERC3 as a critical regulator of the YAP/TAZ stability and a potential therapeutic target for breast cancer.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-04T12:06:06.41Z</modification><creation>2025-04-04T12:06:06.41Z</creation></dates><accession>S-EPMC9929636</accession><cross_references><pubmed>36598329</pubmed><doi>10.15252/embj.2022111549</doi></cross_references></HashMap>